X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay
- PMID: 34128148
- DOI: 10.1007/s10157-021-02099-4
X-chromosome inactivation patterns in females with Fabry disease examined by both ultra-deep RNA sequencing and methylation-dependent assay
Abstract
Background: Fabry disease is an X-linked inherited lysosomal storage disorder caused by mutations in the gene encoding α-galactosidase A. Males are usually severely affected, while females have a wide range of disease severity. This variability has been assumed to be derived from organ-dependent skewed X-chromosome inactivation (XCI) patterns in each female patient. Previous studies examined this correlation using the classical methylation-dependent method; however, conflicting results were obtained. This study was established to ascertain the existence of skewed XCI in nine females with heterozygous pathogenic variants in the GLA gene and its relationship to the phenotypes.
Methods: We present five female patients from one family and four individual female patients with Fabry disease. In all cases, heterozygous pathogenic variants in the GLA gene were detected. The X-chromosome inactivation patterns in peripheral blood leukocytes and cells of urine sediment were determined by both classical methylation-dependent HUMARA assay and ultra-deep RNA sequencing. Fabry Stabilization Index was used to determine the clinical severity.
Results: Skewed XCI resulting in predominant inactivation of the normal allele was observed only in one individual case with low ⍺-galactosidase A activity. In the remaining cases, no skewing was observed, even in the case with the highest total severity score (99.2%).
Conclusion: We conclude that skewed XCI could not explain the severity of female Fabry disease and is not the main factor in the onset of various clinical symptoms in females with Fabry disease.
Keywords: Female Fabry disease; HUMARA; Ultra-deep RNA sequencing; X-chromosome inactivation.
© 2021. Japanese Society of Nephrology.
Similar articles
-
DNA methylation impact on Fabry disease.Clin Epigenetics. 2021 Feb 2;13(1):24. doi: 10.1186/s13148-021-01019-3. Clin Epigenetics. 2021. PMID: 33531072 Free PMC article. Review.
-
Female Fabry disease patients and X-chromosome inactivation.Gene. 2018 Jan 30;641:259-264. doi: 10.1016/j.gene.2017.10.064. Epub 2017 Oct 25. Gene. 2018. PMID: 29079200
-
Disease manifestations and X inactivation in heterozygous females with Fabry disease.Acta Paediatr Suppl. 2006 Apr;95(451):30-8. doi: 10.1111/j.1651-2227.2006.tb02386.x. Acta Paediatr Suppl. 2006. PMID: 16720462
-
X-chromosome inactivation in female patients with Fabry disease.Clin Genet. 2016 Jan;89(1):44-54. doi: 10.1111/cge.12613. Epub 2015 Jun 22. Clin Genet. 2016. PMID: 25974833
-
X Chromosome Inactivation in Carriers of Fabry Disease: Review and Meta-Analysis.Int J Mol Sci. 2021 Jul 17;22(14):7663. doi: 10.3390/ijms22147663. Int J Mol Sci. 2021. PMID: 34299283 Free PMC article. Review.
Cited by
-
Females with Fabry disease: an expert opinion on diagnosis, clinical management, current challenges and unmet needs.Front Cardiovasc Med. 2025 Mar 12;12:1536114. doi: 10.3389/fcvm.2025.1536114. eCollection 2025. Front Cardiovasc Med. 2025. PMID: 40144933 Free PMC article. Review.
-
The Benefits of Early versus Late Therapeutic Intervention in Fabry Disease.Case Rep Genet. 2022 Dec 30;2022:3208810. doi: 10.1155/2022/3208810. eCollection 2022. Case Rep Genet. 2022. PMID: 36619006 Free PMC article.
-
Dysregulated DNA methylation in the pathogenesis of Fabry disease.Mol Genet Metab Rep. 2022 Sep 26;33:100919. doi: 10.1016/j.ymgmr.2022.100919. eCollection 2022 Dec. Mol Genet Metab Rep. 2022. PMID: 36186841 Free PMC article.
-
DNA methylation impact on Fabry disease.Clin Epigenetics. 2021 Feb 2;13(1):24. doi: 10.1186/s13148-021-01019-3. Clin Epigenetics. 2021. PMID: 33531072 Free PMC article. Review.
-
Reduced α-galactosidase A activity in zebrafish (Danio rerio) mirrors distinct features of Fabry nephropathy phenotype.Mol Genet Metab Rep. 2022 Feb 17;31:100851. doi: 10.1016/j.ymgmr.2022.100851. eCollection 2022 Jun. Mol Genet Metab Rep. 2022. PMID: 35242583 Free PMC article.
References
-
- Mehta A, et al. Fabry disease: a review of current management strategies. QJM. 2010;103(9):641–59. - DOI
-
- Desnick RJ. Fabry disease, an under-recognized multisystemic disorder:expert recommendations for diagnosis, management, and enzyme replacement therapy. Ann Intern Med. 2003;138:338–46. - DOI
-
- Saito S, Ohno K, Sakuraba H. Fabry-database.org: database of the clinical phenotypes genotypes and mutant ⍺-galactosidase A sturctures in Fabry disease. J Hum Genet. 2011;56(6):467–8. - DOI
-
- Fuller M, Meikle P, Hopwood J. Epidemiology of lysosomal storage diseases: an overview, in Fabry Disease: perspectives from 5 Years of FOS. In: Mehta A, Beck M, Sunder-Plassmann G, editors. Pharmagenesis. England: Oxford; 2006.
-
- Sawada T, et al. Newborn screening for Fabry disease in the western region of Japan. Mol Genet Metab Rep. 2020;22:100562. - DOI
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical